Klaria Pharma Holding AB (publ.) (Klaria Pharma Holding AB) Aktie

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.